Incidence of extraovarian clear cell cancers in women with surgically diagnosed endometriosis: A cohort study.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2021
Historique:
received: 02 02 2021
accepted: 01 06 2021
entrez: 29 6 2021
pubmed: 30 6 2021
medline: 18 11 2021
Statut: epublish

Résumé

Endometriosis is associated with increased risk of clear cell ovarian cancer and has even suggested being an etiological factor for this cancer. Association between endometriosis and extraovarian clear cell cancers is unclear. This study aimed to assess the association between surgically diagnosed endometriosis and risk of extraovarian clear cell cancers according to the type of endometriosis (i.e., ovarian, peritoneal, and other endometriosis) and the site of clear cell cancer. In this register-based historic cohort study we identified all women with surgically diagnosed endometriosis from the Finnish Hospital Discharge Registry 1987-2012. Data on extraovarian clear cell cancers of these women were obtained from the Finnish Cancer Registry. The follow-up started January 1st, 2007 or at endometriosis diagnosis (if later), and ended at emigration, death or on the December 31st, 2014. Standardized incidence ratios were calculated for each site of clear cell carcinoma (intestine, kidney, urinary tract, gynecological organs other than ovary), using the Finnish female population as reference. The endometriosis cohort consisted of 48,996 women, including 22,745 women with ovarian and 19,809 women with peritoneal endometriosis. Altogether 23 extraovarian clear cell cancers were observed during 367,386 person-years of follow-up. The risk of extraovarian clear cell cancer was not increased among all women with surgically diagnosed endometriosis (standardized incidence ratio 0.89, 95% confidence interval 0.56-1.33) nor in different types of endometriosis. The incidence of clear cell cancer in any specific site was not increased either. The risk of extraovarian clear cell cancers in women with surgically diagnosed endometriosis is similar to that in the general population in Finland.

Sections du résumé

BACKGROUND
Endometriosis is associated with increased risk of clear cell ovarian cancer and has even suggested being an etiological factor for this cancer. Association between endometriosis and extraovarian clear cell cancers is unclear. This study aimed to assess the association between surgically diagnosed endometriosis and risk of extraovarian clear cell cancers according to the type of endometriosis (i.e., ovarian, peritoneal, and other endometriosis) and the site of clear cell cancer.
METHODS
In this register-based historic cohort study we identified all women with surgically diagnosed endometriosis from the Finnish Hospital Discharge Registry 1987-2012. Data on extraovarian clear cell cancers of these women were obtained from the Finnish Cancer Registry. The follow-up started January 1st, 2007 or at endometriosis diagnosis (if later), and ended at emigration, death or on the December 31st, 2014. Standardized incidence ratios were calculated for each site of clear cell carcinoma (intestine, kidney, urinary tract, gynecological organs other than ovary), using the Finnish female population as reference.
RESULTS
The endometriosis cohort consisted of 48,996 women, including 22,745 women with ovarian and 19,809 women with peritoneal endometriosis. Altogether 23 extraovarian clear cell cancers were observed during 367,386 person-years of follow-up. The risk of extraovarian clear cell cancer was not increased among all women with surgically diagnosed endometriosis (standardized incidence ratio 0.89, 95% confidence interval 0.56-1.33) nor in different types of endometriosis. The incidence of clear cell cancer in any specific site was not increased either.
CONCLUSIONS
The risk of extraovarian clear cell cancers in women with surgically diagnosed endometriosis is similar to that in the general population in Finland.

Identifiants

pubmed: 34185779
doi: 10.1371/journal.pone.0253270
pii: PONE-D-21-03577
pmc: PMC8241117
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0253270

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

J Minim Invasive Gynecol. 2020 Feb;27(2):373-389
pubmed: 31618674
Int J Cancer. 2018 Dec 1;143(11):2725-2731
pubmed: 29981163
Br J Cancer. 2014 Apr 2;110(7):1878-90
pubmed: 24518590
Hum Reprod. 2007 Nov;22(11):3021-6
pubmed: 17855408
Urology. 2012 Jun;79(6):e84-5
pubmed: 22656428
J Obstet Gynaecol Res. 2020 Jun;46(6):917-923
pubmed: 32212420
Int J Gynecol Pathol. 2001 Apr;20(2):133-9
pubmed: 11293158
J Obstet Gynaecol Res. 2013 Jan;39(1):455-61
pubmed: 22845018
Int J Surg Oncol. 2015;2015:790235
pubmed: 25685552
N Engl J Med. 1977 Jan 13;296(2):67-70
pubmed: 830309
Lancet Oncol. 2012 Apr;13(4):385-94
pubmed: 22361336
Am J Pathol. 2013 Apr;182(4):1163-70
pubmed: 23416164
Curr Oncol Rep. 2013 Dec;15(6):566-72
pubmed: 24114188
Acta Obstet Gynecol Scand. 2018 Jan;97(1):59-67
pubmed: 29028285
Am J Surg Pathol. 2002 Feb;26(2):190-7
pubmed: 11812940
Hum Reprod. 2019 Jan 01;34(1):69-78
pubmed: 30428062
Cancer. 2006 Sep 1;107(5 Suppl):1128-41
pubmed: 16802325
Int J Clin Oncol. 2010 Oct;15(5):489-92
pubmed: 20221659
Pathol Res Pract. 2017 May;213(5):447-452
pubmed: 28285963
N Engl J Med. 2017 May 11;376(19):1835-1848
pubmed: 28489996
Gynecol Oncol. 2012 Jan;124(1):164-9
pubmed: 22032835
Int J Gynecol Cancer. 2008 Sep-Oct;18(5):1118-21
pubmed: 17986241
J Ovarian Res. 2014 Oct 02;7:86
pubmed: 25366349
Gynecol Oncol. 2006 Dec;103(3):1130-2
pubmed: 16996119
Semin Reprod Med. 2017 Jan;35(1):98-101
pubmed: 27992931
Gynecol Oncol. 2017 Sep;146(3):566-571
pubmed: 28689666
J Pathol. 2011 Jul;224(3):328-33
pubmed: 21590771
Obstet Gynecol. 2002 Oct;100(4):788-95
pubmed: 12383550
Nat Rev Urol. 2010 May;7(5):245-57
pubmed: 20448658
J Cutan Pathol. 2012 Nov;39(11):1035-41
pubmed: 22882475
Acta Oncol. 2018 Apr;57(4):440-455
pubmed: 29226751
J Ovarian Res. 2016 Jan 12;9:1
pubmed: 26754828
Scand J Public Health. 2012 Aug;40(6):505-15
pubmed: 22899561
Int J Gynecol Cancer. 2014 Nov;24(9 Suppl 3):S90-5
pubmed: 25341588
Appl Immunohistochem Mol Morphol. 2011 Jul;19(4):384-5
pubmed: 21293258

Auteurs

Liisu Saavalainen (L)

Department of Obstetrics and Gynaecology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.

Heini Lassus (H)

Department of Obstetrics and Gynaecology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.

Anna But (A)

Department of Public Health, Biostatistics Consulting, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.

Mika Gissler (M)

Information Services Department, Finnish Institute for Health and Welfare (THL), Helsinki, Finland.
Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden.

Oskari Heikinheimo (O)

Department of Obstetrics and Gynaecology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.

Eero Pukkala (E)

Finnish Cancer Registry-Institute for Statistical and Epidemiological Cancer Research, Helsinki, Finland.
Faculty of Social Sciences, Tampere University, Tampere, Finland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH